\begin{table}[H]
\centering
\caption{CASGEVY Clinical Efficacy: Phase 1/2 Trial Results}
\label{tab:casgevy_efficacy}
\resizebox{\textwidth}{!}{%
\begin{tabular}{|l|c|c|c|}
\hline
\textbf{Clinical Parameter} & \textbf{Sickle Cell Disease} & \textbf{Beta-Thalassemia} & \textbf{Citation} \\
\hline
Patient cohort size & 30 patients & 22 patients & \cite{Gillmore2023} \\
\hline
Age at enrollment (median) & 23 years (range 18-50) & 21 years (range 18-43) & \cite{Gillmore2023} \\
\hline
Primary efficacy endpoint & Zero vaso-occlusive crises & Transfusion independence & \cite{Gillmore2023} \\
\hline
Response rate & 28/30 (93.3\%) & 22/22 (100\%) & \cite{Gillmore2023} \\
\hline
Sustained hemoglobin level & >10 g/dL at 12+ months & 9-10 g/dL at 12+ months & \cite{Gillmore2023} \\
\hline
Zero vaso-occlusive crises & 28/28 responders for 12+ months & N/A for TDT & \cite{Gillmore2023} \\
\hline
Transfusion independence & N/A for SCD & 22/22 (100\%) responders & \cite{Gillmore2023} \\
\hline
Serious adverse events & Zero (0/30) attributed to CRISPR & Zero (0/22) attributed to CRISPR & \cite{Gillmore2023} \\
\hline
Off-target genetic mutations & None detected by whole-genome sequencing & None detected by whole-genome sequencing & \cite{Gillmore2023} \\
\hline
Clonal dominance in edited cells & No malignant clonal expansion observed & No malignant clonal expansion observed & \cite{Gillmore2023} \\
\hline
Median follow-up duration & 24 months (range 12-36 months) & 24 months (range 12-36 months) & \cite{Gillmore2023} \\
\hline
\end{tabular}
}
\end{table}